Central Drugs Standard Control Organisation

Polity & Governance glossary

Also called: CDSCO, DCGI · Topic: Statutory, Regulatory and Quasi-judicial Bodies · NCERT: Beyond NCERT

Meaning

The Central Drugs Standard Control Organisation (CDSCO) is India's national drug regulator. It works under the Union Ministry of Health and Family Welfare (MoHFW) and is headed by the Drugs Controller General of India (DCGI). It carries out the Centre's duties under the Drugs and Cosmetics Act, 1940: approving new drugs, overseeing clinical trials, controlling imports and setting quality standards. State Drug Controllers license most manufacturers and shops and enforce the law on the ground.

It matters because every medicine, medical device and cosmetic sold in India passes through this system. When drugs fail quality tests, public health suffers and India's name as a drug exporter is damaged.

Explanation

How the system is built: Centre and states share the work

  • Legal base: the Drugs and Cosmetics Act, 1940 is the parent law. The Rules made under it are dated 21 December 1945.

  • Recent government notices call them the "Drugs Rules, 1945", while India Code uses "Drugs and Cosmetics Rules, 1945". Both names mean the same rules.

  • Constitutional base: "Drugs and poisons" is Entry 19 of the Concurrent List (List III, Seventh Schedule), so both Parliament and state legislatures can make laws on it.

  • Central level (CDSCO and DCGI):
  • approves new drugs and clinical trials under the New Drugs and Clinical Trials Rules, 2019;
  • controls imports through its port offices, which check drugs, medical devices and cosmetics at notified ports of entry (the only places where these goods may legally enter India);
  • regulates medical devices under the Medical Devices Rules, 2017;

  • sets standards and works with State Drug Controllers on inspections.

  • State level (State Drug Controllers):

  • license most manufacturing units and chemist shops;
  • send inspectors to check shops and factories and take samples;
  • prosecute offenders.
  • A drug that enters through a central port is sold in state markets, so state capacity decides how well the law works in practice.

Quality control tools

  • Schedule M (Good Manufacturing Practices, GMP): the rulebook for how medicines must be made safely, covering premises, plant and equipment.
  • It was revised by G.S.R. 922(E) dated 28 December 2023. The revision added a Pharmaceutical Quality System, Quality Risk Management, and Qualification & Validation.
  • It became binding on large manufacturers (turnover above ₹250 crore) from 28 June 2024.

  • Smaller firms (turnover of ₹250 crore or less) got a conditional extension to 31 December 2025.

  • Holding a batch: the licensing authority can tell a maker not to sell a batch until the authority issues a certificate authorising its sale.

  • Drug schedules: lists that decide how a drug may be sold (H, H1, K, X). For example, formulations with more than 12% v/v alcohol in quantities above 30 mL lost their Schedule K exemption and were moved to Schedule H1.
  • Inspections: CDSCO and State Drug Controllers carried out risk-based inspections (visits aimed first at the units most likely to break the rules) of 400 premises, including MSMEs. There have been more than 960 such inspections since December 2022.
  • Quality terms:
  • NSQ (Not of Standard Quality): the drug fails an official quality test.
  • Spurious: the drug is fake.
  • India's largest national drug survey tested 47,954 samples. It found 3.16% NSQ and 0.0245% spurious.

Limits and weak spots

  • Too few staff:
  • CDSCO's sanctioned posts rose from 111 in 2008 to 492 in January 2021. That is still small for a national regulator.
  • The Mashelkar Committee asked for more and better-trained drug inspectors.

  • In 2026 the Parliamentary Standing Committee on Health found long-running vacancies among Drugs Controllers. It also said CDSCO's generalist administrative set-up cannot handle complex technical evaluation.

  • Weak state capacity:

  • CAG found 88% of drugs inspector posts vacant in Karnataka. In that audit, 59% of drugs were already used up before their test results arrived.

  • In Punjab, only 52 of the 120 required drug inspectors were in post in March 2015.

  • Old law, new markets:

  • The 1940 Act was written long before the internet.
  • Draft e-pharmacy rules, G.S.R. 817(E) of 28 August 2018, are still not final because the matter is pending in several High Courts.
  • This leaves online sales of unapproved "wellness" products in a grey zone, outside clear rules.

In the Constitution and practice

  • Constitution:
  • Entry 19, List III (drugs and poisons) creates the Centre–state sharing.
  • Article 47 (a Directive Principle) asks the State to improve public health. It also asks the State to ban drugs that harm health, except for medical use.

  • Courts read a right to health into Article 21 (right to life). Drug quality assurance supports that right.

  • Law:

  • Drugs and Cosmetics Act, 1940 and its Rules of 1945.
  • New Drugs and Clinical Trials Rules, 2019.

  • Medical Devices Rules, 2017.

  • Delegated legislation: most changes come as Rules, not as new Acts.

  • Delegated legislation means rules made by the executive under powers that an Act gives it.
  • The Health Ministry usually publishes a draft notification in the Gazette, invites objections, and then issues the final rule.

  • Example: G.S.R. 927(E) (29 December 2025) ended the exemption that let cough syrups be sold in small villages without a licensed pharmacy.

  • Planned replacement: the Drugs, Medical Devices and Cosmetics Bill, 2022 would replace the 1940 Act. Among other things, it would let the government set conditions for selling drugs online.

  • Practice: cough-syrup contamination episodes led to a run of quality reforms. These included the Schedule M revision, risk-based inspections and the tighter sale rules above.
  • Where it sits among public bodies: it is a regulatory body (an agency that licenses, sets standards and enforces rules in one sector). It sits beside sector regulators such as FSSAI and the NMC.

Don't confuse with

  • Department of Pharmaceuticals: this department is under the Ministry of Chemicals & Fertilizers and deals with the drug industry. CDSCO is under MoHFW and deals with drug safety and quality.
  • FSSAI: it is also under the Health Ministry, but it regulates food under its own founding law, the FSS Act 2006. CDSCO has no separate founding Act. It is the Health Ministry's office for carrying out the Centre's duties under the Drugs and Cosmetics Act, 1940.
  • State Drug Controllers: these are state officials who license most makers and shops and enforce the law. CDSCO handles new drugs, clinical trials and imports at the national level.
  • National Medical Commission: it regulates medical education and doctors under the NMC Act 2019. CDSCO regulates medicines and devices.

Prelims Hooks

  • CDSCO is under the Ministry of Health and Family Welfare and is headed by the DCGI. It is not under the Ministry of Chemicals & Fertilizers.
  • Parent law: Drugs and Cosmetics Act, 1940. Rules: 1945. Schedule M (GMP) is in the Rules, not the Act.
  • Revised Schedule M: G.S.R. 922(E), 28 December 2023. Binding on firms with turnover above ₹250 crore from 28 June 2024.
  • New drugs and clinical trials: NDCT Rules, 2019. Medical devices: Medical Devices Rules, 2017.
  • "Drugs and poisons" is in the Concurrent List (Entry 19). That is why Centre and states share drug regulation.
  • Trap: "Spurious" means fake, while "NSQ" means the drug failed a quality test. They are different findings. In the national survey, NSQ was 3.16% and spurious was 0.0245%.

Mains Points

  • A divided structure that is short of staff:
  • CDSCO approves at the national level, but states enforce in the market.
  • Inspector vacancies (88% in Karnataka) and slow test results mean faults are often found after patients have taken the drug.

  • Reform ideas: fill Drugs Controller posts on a fixed timeline, create a specialist technical cadre in CDSCO, and empanel accredited testing labs.

  • An old law versus new risks:

  • The 1940 Act does not cover e-pharmacies or modern "wellness" products well.
  • The unfinished 2018 e-pharmacy rules and the pending 2022 Bill show that law reform is slow.

  • Finishing both would give the regulator clear powers over online sales.

  • Independence and accountability:

  • Like other regulators, CDSCO is controlled by its ministry and can be pressured by industry.
  • This creates a risk of regulatory capture (when a regulator ends up serving the industry it regulates instead of the public).
  • The balance to strike: cheaper compliance for MSMEs (as with the Schedule M extensions) against strict quality standards that protect patients' right to health under Article 21 and India's export reputation.

Read more